Boehringer Ingelheim has announced it will act quickly to settle complaints from the FDA over violations at its headquarters in Germany. The FDA published a warning letter on its website citing the drugmaker's failure to hold a thorough investigation of foreign particles in the active pharmaceutical ingredient of a treatment that was not named. The letter also claimed that Boehringer did not reject treatments that failed to meet accepted specifications or standards and other pertinent quality-control benchmarks.

Full Story:
PharmaTimes (U.K.)

Related Summaries